Fluconazole in the treatment of onychomycosis caused by dermatophytes

Kuokkanen, K; Alava, S

doi:10.3109/09546639209088703

Cited by 50 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies of ß uconazole in onychomycosis show high cure rates but a need of long treatment time along with demonstration of some potentially signiÞ cant drug interactions. [29] Itraconazole, a broad-spectrum synthetic antifungal triazole approved in 1995 for the treatment of onychomycosis, represents an advancement beyond earlier therapies, due to its broad spectrum of activity, its high afÞ nity for keratin and its pharmacokinetic proÞ le. It is highly effective in the treatment of dermatophyte, yeast and some non-dermatophytic mould infections of the nails.…”

Section: Treatment Of Onychomycosismentioning

confidence: 99%

Onychomycosis - epidemiology, diagnosis and management

Kaur

Kashyap

2008

Indian J Med Microbiol

157

View full text Add to dashboard Cite

Onychomycosis is a fungal infection of nails caused by dermatophytes, yeasts or nondermatophyte molds and represents about 30% of mycotic cutaneous infections. Increasingly onychomychosis is being viewed as more than a mere cosmetic problem. In spite of improved personal hygiene and living environment, onychomycosis continues to spread and persist. The prevalence rate of onychomycosis is determined by age, predisposing factor, social class, occupation, climate, living environment and frequency of travel. Onychomycosis in immunocompromised patients can pose a more serious health problem. Dermatophytes are the most frequently implicated causative agents in onychomycosis. Previously regarded as contaminants, yeasts are now increasingly recognised as pathogens in Þ ngernail infections, as are some moulds. Clinical diagnosis of onychomycosis is based on the patients' history; a physical examination, microscopy and culture of nail specimens. The treatment of onychomycosis has been attempted throughout the ages, but only in the last two decades have safe, effective systemic treatments been available for this chronic superÞ cial fungal disease. Oral Griseofulvin and Ketoconazole; once the agents of choice for the treatment of onychomycosis, have been superseded by newer systemic compounds that have a higher cure and lower relapse rates, cause fewer side effects and are suitable for short-term dosing.

show abstract

Section: Treatment Of Onychomycosismentioning

confidence: 99%

Onychomycosis - epidemiology, diagnosis and management

Kaur

Kashyap

2008

Indian J Med Microbiol

157

View full text Add to dashboard Cite

show abstract

“…Fluconazole, a bis-triazole antifungal agent characterized by good bioavailability, low protein binding, and a long half-life of about 30 h in serum, has been demonstrated to be effective in the treatment of onychomycosis at a dosage of 150 mg once weekly over a period of several months (11). Yet the clinical use in this indication still awaits further confirmation.…”

mentioning

confidence: 99%

Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. German Collaborative Dermatophyte Drug Susceptibility Study Group

Körting

Ollert

Abeck

1995

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Thirty-two strains of Trichophyton rubrum and 16 strains of Trichophyton mentagrophytes isolated from patients with tinea unguium in various parts of Germany were subjected to a microdilution test with six systemic or topical antimycotic agents. Apart from griseofulvin, there were no species-specific differences between the two species. Terbinafine was the most active antimycotic agent, with a MIC not exceeding 0.05 g/ml.

show abstract

“…Eine Studie von Kuokkanen et al [47] beschäftigte sich 1992 zum ersten Mal mit den klinischen und mykologischen Erfolgen einer Langzeittherapie von Onychomykosepatienten (bei kulturellem Nachweis von Trichophyton rubrum) mit 150 mg Fluconazol einmal wöchentlich. Dabei wurden 46 Fingerund/oder Zehennägel entweder bis zum Zeitpunkt einer klinischen Heilung oder maximal zwölf Monate lang behandelt und in vierwöchigen Abstän-den Nagelproben klinisch und mykologisch (Kultur und Mikroskopie) untersucht.…”

Section: Fluconazol Als Systemische Therapiealternativeunclassified

Therapie der Onychomykose

Reisberger

Szeimies²

2000

Med Klin

View full text Add to dashboard Cite

Topical urea and bifonazole therapy was available in the past as well as systemic antimycotic therapy with just griseofulvin or ketoconazole. Nowadays a different spectrum of easily applicable, safe and effective therapeutic measures is on the physician's hands. Besides topical therapy with ciclopirox and amorolfine oral treatment with itraconazole, terbinafine and fluconazole is available. Combination therapy of terbinafine orally in addition with topical application of ciclopirox may possibly optimize the therapeutic approach considering the respective response rates however, no clinical study evaluating this hypothesis has been performed so far.

show abstract

Fluconazole in the treatment of onychomycosis caused by dermatophytes

Cited by 50 publications

References 13 publications

Onychomycosis - epidemiology, diagnosis and management

Onychomycosis - epidemiology, diagnosis and management

Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. German Collaborative Dermatophyte Drug Susceptibility Study Group

Therapie der Onychomykose

Contact Info

Product

Resources

About